Lamifiban. Platelet antiaggregatory, fibrinogen gpIIb/IIIa receptor antagonist

Drugs of the Future

Volumn 24, Issue 3, 1999, Pages 261-268

  Cases, A ^a   Rabasseda, X ^b   Castaner J ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; 3 ACETOXY 5 [2 (DIMETHYLAMINO)ETHYL] 2,3 DIHYDRO 8 METHYL 2 (4 METHYLPHENYL) 1,5 BENZOTHIAZEPIN 4(5H) ONE MALEATE; 4 (4 AMIDINOBENZOYLGLYCYL) 3 METHOXYCARBONYLMETHYL 2 OXO 1 PIPERAZINEACETIC ACID; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; 4 [[3 [4 [IMINO[(METHOXYCARBONYL)AMINO]METHYL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL] 1 PIPERAZINEACETIC ACID ETHYL ESTER; ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CT 50352; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; GR 233548; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; RWJ 533078; S 1197; SDZ GPI 562; SIBRAFIBAN; T 250; TIROFIBAN; UNCLASSIFIED DRUG; YM 028; YM 337;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 0032929006     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.03.527582     Document Type: Review

References (52)

1. Alig, L., Edenhofer, A., Hadváry, P., Hürzeler, M., Knopp, D., Müller, M., Steiner, B., Trzeciak, A., Weller. T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992, 34: 4393-407.
2. Alig, L., Hadvary, P., Hüzeler, M., Müller, M., Steiner, B., Weller, T. (F. Hoffmann-La Roche AG). N-Acyl-α-amino acids derivs. EP 505868, JP 93148204, US 5378712, US 5545658, US 5658928, US 5670515, US 5747522.
3. Graul, A., Martel, A.M., Castañer, J. Xemilofiban. Drugs Fut 1997, 22(5): 508-17.
4. Merlos, M., Graul, A., Castañer, J. Sibrafiban. Drugs Fut 1998, 23(12): 1297-303.
5. Spotlight update: Fibrinogen (gpIIb/IIIa) receptor antagonists. Prous Science Daily Essentials March 1, 1999.
6. Steiner, B., Jones, C.R., van Heiningen, P.N.M., Jonkman, J.H.G., Carroll, R.C., Kouns, W.C. TRAP-induced ex vivo platelet aggregation might be a useful method to predict anti-thrombotic efficacy. Blood 1993, 10(Suppl. 1): Abst 1122.
7. Bednar, R.A., Gaul, S.L., Hamill, T.G., Egbertson, M.S., Shafer, J.A., Hartman, G.D., Gould, R.J., Bednar, B. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther 1998, 285: 1317-26.
8. Kouns, W.C., Weller, T., Hadvary, P., Jennings, L.K., Steiner, B. Identification of a peptidomimetic inhibitor with minimal effects on the conformation of GPIIb-IIIa. Blood 1992, 80(10, Suppl. 1): Abst 650.
9. Steiner, B., Häring, P., Jennings, L., Kouns, W.C. Five independent neo-epitopes on GPIIb-IIIa are differentially exposed by two potent peptidomimetic platelet inhibitors. Thromb Haemost 1993, 69(6): Abst 860.
10. Satoh, T., Kouns, W.C., Steiner, B. GP IIb-IIIa antagonists like lamifiban (Ro 44-9883) that do not induce conformational changes are potent inhibitors of platelet adhesion to fibrinogen. Thromb Haemost 1995, 73(6): Abst 1594.
11. Murphy, N., Jennings, L., Pratico, D., Doyle, C., Fitzgerald, D.J. Functional relevance of LIBS expression in the response to platelet glycoprotein antagonists in vivo. Thromb Haemost 1995, 73(6): Abst 1591.
12. Murphy, N.P., Pratico, D., Fitzgerald, D.J. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. J Pharmacol Exp Ther 1998, 286: 945-51.
13. Kirchhofer, D., Tschopp, T.B., Steiner, B., Baumgartner, H.R. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 1995, 86: 3815-22.
14. Takiguchi, Y., Wada, K., Asai, F., Nishiyama, H., Nakashima, M. Antithrombotic effect of a new inhibitor of platelet glycoprotein IIb-IIIa, Ro 44-9883, in guinea-pig thrombosis model. Jpn J Pharmacol 1993, 61 (Suppl. 1): Abst P-97.
15. Carteaux, J.P., Steiner, B., Roux, S. Ro 44-9883, a new nonpeptidic GPIIb-GPIIIa antagonist prevents platelet loss in a guinea pig model of extracorporeal circulation. Thromb Haemost 1993, 70: 817-21.
16. Carteaux, J.P., Roux, S., Kuhn, H., Tschopp, T., Colombo, V., Hadvéry, P. Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993, 106: 834-41.
17. Dagenais, P., Libersan, D., Merhi, Y., Rousseau, G., Latour, J.-G. GPIIb/IIIa receptor blockade at reperfusion reduces infarct size in the dog. Circulation 1997, 96(8, Suppl.): Abst 4163.
18. Steiner, B., Alig, L., Blackburn, B., Bunting, S., Hürzeler, M., Schmitt, M., Weiss, S., Weller, T. A new class of orally active GPIIb-IIIa antagonists. Blood 1995, 86(10, Suppl. 1): Abst 351.
19. Lave, T., Saner, A., Coassolo, P., Schmitt-Hoffmann, A.H., Chou, R.C. Interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. 4th Int ISSX Meet (Aug 27-31, Seattle) 1995, Abst 268.
20. Lave, T., Saner, A., Coassolo, P., Brandt, R., Schmitt-Hoffmann, A.H., Chou, R.C. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 1996, 48: 573-7.
21. Jones, C.R., Ambros, R.J., Rapold, H.J., Steiner, B., Weller, T., van Heiningen, P., Crijns, H.J.M.J., Jonkman, J.H.G., Hadvary, P. Ro 44-9883: A novel non peptide GPIIb/IIa antagonist in man. Thromb Haemost 1993, 69(6): Abst 65.
22. Lehne, G., Nordal, K.P., Midtvedt, K., Goggin, T., Brosstad, F. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. Thromb Haemost 1998, 79: 1119-25.
23. Anderson, D.R., Zayed, E., Embree, J., Theroux, P., Steiner, B. Flow cytometry as a quantitative measure of the antiplatelet activity of a glycoprotein IIb-IIIa inhibitor. Blood 1995, 86(10, Suppl. 1): Abst 3558.
24. Kouns, W.C., Weller, T., Steiner, B. A rapid flow cytometric method to monitor plasma concentrations of GP IIb-IIIa antagonists in the clinic. Blood 1994, 84(10, Suppl. 1): Abst 1269.
25. Pharand, C., Nasmith, J.B., Badir, B.F., Dubé, B., Cardinal, R., LeBlanc, A.-R. A novel GPIIb-IIIa inhibitor, lamifiban (Ro 44-9883), decreases ST segment-measured ischemia during unstable angina. 6th Int Cong Cardiovasc Pharmacother (Feb 26-29, Sydney) 1996, A1.
26. Théroux, P., Kouz, S., Roy, L. et al. Platelet-membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996, 94: 899-905.
27. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998, 97: 2386-95.
28. Harrington, R.A., Newby, L.K., Moliterno, D.J. et al. Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: Evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial. J Am Coll Cardiol 1997, 29(2, Suppl. A): Abst 1033-38.
29. Moliterno, D.J., Harrington, R.A., Newby, K.L., Armstrong, P.W., Van de Werf, F., White, H.D., Califf, R.M., Topol, E.J. Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON study 1-year follow-up. J Am Coll Cardiol 1998, 31(2, Suppl. A): Abst 854-6.
30. Moliterno, D.J., Harrington, R.A., Newby, K., Bhapkar, M., Emanuelsson, H., Armstrong, P.W., Topol, E.J. Pronounced reduction in long-term ischemic events with platelet IIb/IIIa antagonism among diabetics with unstable angina: PARAGON 6-month results. Circulation 1997, 96(8, Suppl.): Abst 2646.
31. Alexander, J.H., Newby, L.K., Moliterno, D.J., Bhapkar, M., Van de Werf, F., White, H.D., Harrington, R.A., Topol, E.J., Califf, R.M. Relationship of outcomes to treatment with lamifiban in patients undergoing PTCA: Analysis of PARAGON A. J Am Coll Cardiol 1997, 29(2, Suppl. A): Abst 1033-34.
32. Steiner, B., Hofer, U., Wittke, B., Topol, E.J., Califf, R.M., Harrington, R.A., Armstrong, P.W., Van de Werf, F., Moliterno, D.J. Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: Results from PARAGON A. Eur Heart J 1998, 19(Suppl.): Abst 3420.
33. Steiner, B., Hofer, U., Wittke, B., Harrington, R.A., Bhapkar, M.V., Armstrong, P.W., Moliterno, D.J. Plasma level of lamifiban and platelet receptor occupancy best predict clinical outcome in patients with unstable angina: Results from PARAGON A. Circulation 1998, 98(17, Suppl.): Abst 2955.
34. Moliterno, D.J., Harrington, R.A., Califf, R.M., Rapold, H.J., Topol, E.J. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study. J Thromb Thrombolysis 1995, 2: 165-9.
35. Ferguson, J.J., Lau, T.K. New antiplatelet agents for acute coronary syndromes. Am Heart J 1998, 135(5, Part 2): S194-200.
36. Giugliano, R.P., Hyatt, R.R. Jr. Thrombocytopenia with GP IIb/IIIa inhibitors: A meta-analysis. J Am Coll Cardiol 1998, 31(2, Suppl. A): Abst 837-5.
37. Lamifiban development status. F. Hoffman-La Roche AG Company Communication Nov 18, 1998.
38. Roux, S., Bunting, S., Kouns, C., Steiner, B. Overdosing of potent GP IIb-IIIa antagonists differentially prolongs the bleeding time in guinea pigs. Thromb Haemost 1993, 69(6): Abst 66.
39. Harrington, R.A., Moliterno, D.J., Van de Werf, F. et al. Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor lamifiban. J Am Coll Cardiol 1997, 29(2, Suppl. A): Abst 1033-31.
40. Krucoff, M.W., Harrington, R.A., Moliterno, D.J. et al. The paradigm for anti-platelet effect on continuous 12-lead ST-segment recovery in acute MI. J Am Coll Cardiol 1997, 29(2, Suppl. A): Abst 738-3.
41. Harrington, R.A., Moliterno, D.J., Newby, K. et al. Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation acute coronary syndromes. Circulation 1997, 96(8, Suppl.): Abst 2645.
42. Théroux, P., Kouz, S., Knudtson, M.L., Kells, C., Nasmith, J., Roy, L., Dalle Ave, S., Steiner, B., Xiao, Z., Rapold, H.J. A randomized double-blind controlled trial with the non-peptide platelet GP IIb/IIIa antagonist Ro 44-9883 in unstable angina. Circulation 1994, 90(4, Part 2): Abst 1243.
43. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: The PARAGON study. Circulation 1996, 94(8, Suppl.): Abst 3234.
44. Moliterno, D.J., Harrington, R.A., Krucoff, M.W. et al. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial. Circulation 1996, 94(8, Suppl.): Abst 3232.
45. Moliterno, D.J., Topol, E.J. Meta-analysis of platelet GP IIb/IIIa antagonist randomized clinical trials in ischemic heart disease: Consistent, durable, salutary effects. Circulation 1997, 96(8, Suppl.): Abst 2652.
46. Newby, K., Harrington, R.A., Bhapkar, M., Granger, C.B., Rames, A., Moliterno, D.J. Tight control of aPTT in acute coronary syndrome patients using an automated strategy for bedside heparin adjustment: Results from the PARAGON A trial. Circulation 1997, 96(8, Suppl.): Abst 4200.
47. Alig, L., Edenhofer, A., Hadváry, P., Hürzeler, M., Knopp, D., Müller, M., Steiner, B., Trzeciak, A., Weller, T. Low molecular weight, non-peptide fibrinogen receptor antagonists. 205th ACS Natl Meet (March 28-April 2, Denver) 1993, Abst MEDI 1.
48. Carroll, R.C., Steiner, B., Kouns, W.C. The effects of Ro 43-5054 and Ro 44-9883, peptidomimetic inhibitors of the GPIIb-IIIa fibrinogen binding site, on platelet stimulus-response coupling. Thromb Haemost 1993, 69(6): Abst 868.
49. Larsson, A., Lindahl, T.L. Inhibition of fibrinogen binding to platelets by MK-852 and Ro 44-9883. Two low molecular weight gpIIb/IIIa antagonists. Thromb Haemost 1995, 73(6): Abst 375.
50. Adgey, A.A.J. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 1998,19(Suppl. D): D10-21.
51. Adgey, A.A.J. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998, 135: 843-55.
52. Steiner, B., Kouns, W.C., Roux, S., Weller, T., Rapold, H.J., Jones, R.C. Synthetic non-peptide GP IIb-IIIa antagonists for the treatment and prevention of arterial thrombosis. Can J Physiol Pharmacol 1994, 72(Suppl. 1): Abst S24.3.